Car-t is amazing - currently as per previous announcements works on blood cancers - with approx 80% Orr in trials and 50% complete response. Approved in the US for 2 indications, I understand as at early 2019 for b-cell lymphoma and b-cell lymphoblastic leukemia - however sustained remissions are anticipated in approx 40% patients (.https://www.ascopost.com/issues/september-10-2019/update-on-fda-approved-car-t-cell-gene-therapy-for-b-cell-lymphomas/ ) the current 27% complete response from PTX200 in r/r patients In AML is imho under appreciated by the market - with enrolments the trial still ongoing and everyday an announcement regarding another CR (life saved) imminent; in this context
